Thomas Collet, PhD

Thomas Collet, PhD has extensive experience in the life sciences industry, with a focus on developing therapeutics for various diseases and disorders. Thomas is currently serving as the President & CEO of Bilayer Therapeutics, where they are leading the development of first-in-class therapeutics for GI disease and metabolic disorders such as obesity and Type 2 diabetes. Prior to their current role, Dr. Collet worked as a Principal at Collet Consulting LLC, providing life science consulting services from strategy to implementation and from discovery to commercialization. Thomas also served as a Visiting Scholar at The Wyss Institute at Harvard University.

In the past, Dr. Collet held leadership positions at several biopharmaceutical companies. Thomas was the President & CEO & Co-Founder of Phrixus Pharmaceuticals, Inc., focusing on rare disease and orphan drug development, specifically for Duchenne muscular dystrophy. Thomas also served as the President & CEO & Co-Founder of Meditrina Pharmaceuticals, Inc., with a focus on women's health and the repurposing of drugs for conditions such as endometriosis and uterine fibroids.

Additionally, Dr. Collet was the President & CEO & Co-Founder of ProNAi Therapeutics, Inc., a biopharmaceutical company focused on oncology therapeutics. Thomas played a key role in raising initial funding, assembling a team, and executing product development agreements. Under their leadership, the company went public and later was sold to GSK for $1.9 billion.

Dr. Collet also co-founded Neural Intervention Technologies, Inc., a company developing neurovascular medical devices for conditions such as hemorrhagic stroke and aneurysms. Thomas served as the President & CEO during the early stages of the company.

Before their entrepreneurial endeavors, Dr. Collet held leadership roles at Rubicon Genomics, Inc., where they served as the President & CEO, and at Tullis-Dickerson & Co., Inc., where they were a Vice President involved in early-stage and life science investing. Thomas also served as the VP of Business Development at Monsanto Company (Integrated Protein Technologies), focusing on the production of therapeutic proteins and antibodies in green plants.

Overall, Dr. Collet's work experience showcases their expertise in the biopharmaceutical industry, their leadership skills, and their ability to drive successful development and commercialization of novel therapeutics.

Thomas Collet, PhD completed their education in a disciplined and focused manner, acquiring an impressive educational history. Beginning in 1983, they attended RWTH Aachen University where they pursued a Vordiplom (B.Sc.) in Chemistry. Thomas dedicated their time and efforts to this program until their graduation in 1985.

With a strong foundation in Chemistry and a thirst for knowledge, Thomas Collet proceeded to further elevate their expertise by pursuing a higher degree. In 1985, they were accepted into the prestigious Massachusetts Institute of Technology, where they embarked on an extensive doctoral program. Over six years of dedicated research and academic pursuit, Thomas successfully completed their studies, culminating in the conferral of a Ph.D. in Biological Chemistry in 1991.

Thomas Collet's educational journey reflects their commitment to the field of chemistry and their dedication to studying and understanding its various dimensions. Their academic achievements highlight their capability to undertake rigorous scientific endeavors and contribute significantly to the scientific community.